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Abstract β-ureidopropionase (βUP) deficiency is an autoso-
mal recessive disease characterized by N-carbamyl-β-amino
aciduria. To date, only 16 genetically confirmed patients with
βUP deficiency have been reported. Here, we report on the
clinical, biochemical and molecular findings of 13 Japanese
βUP deficient patients. In this group of patients, three novel
missense mutations (p.G31S, p.E271K, and p.I286T) and a
recently described mutation (p.R326Q) were identified. The
p.R326Q mutation was detected in all 13 patients with eight
patients being homozygous for this mutation. Screening for
the p.R326Q mutation in 110 Japanese individuals showed an
allele frequency of 0.9 %. Transient expression of mutant
βUP enzymes in HEK293 cells showed that the p.E271K
and p.R326Q mutations cause profound decreases in activity
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(≤ 1.3 %). Conversely, βUP enzymes containing the p.G31S
and p.I286T mutations possess residual activities of 50 and
70%, respectively, suggestingwe cannot exclude the presence
of additional mutations in the non-coding region of the UPB1
gene. Analysis of a human βUP homology model revealed
that the effects of the mutations (p.G31S, p.E271K, and
p.R326Q) on enzyme activity are most likely linked to im-
proper oligomer assembly. Highly variable phenotypes rang-
ing from neurological involvement (including convulsions
and autism) to asymptomatic, were observed in diagnosed
patients. High prevalence of p.R326Q in the normal
Japanese population indicates that βUP deficiency is not as
rare as generally considered and screening forβUP deficiency
should be included in diagnosis of patients with unexplained
neurological abnormalities.
Introduction
Pyrimidine nucleotides play an important role in various bio-
logical processes, including synthesis of RNA, DNA, phos-
pholipids, uridine diphosphate glucose and glycogen.
Intracellular pools of pyrimidines are produced de novo
through salvage and catabolic pathways (Huang and Graves
2003; Traut 1994), and in humans, the pyrimidine bases uracil
and thymine, are degraded via three enzymatic steps
(Wasternack 1980). Dihydropyrimidine dehydrogenase
(DPD, EC 1.3.1.2) is the initial and rate-limiting enzyme,
catalyzing uracil and thymine reduction to 5,6-dihydrouracil
and 5,6-dihydrothymine, respectively. The second enzyme,
dihydropyrimidinase (DHP, EC 3.5.2.2), catalyzes the hydro-
lytic ring opening of the dihydropyrimidines. The third step,
catalyzed by β-ureidopropionase (βUP) (EC 3.5.1.6), results
in conversion of N-carbamyl-β-alanine and N-carbamyl-β-
aminoisobutyric acid into β-alanine and β-aminoisobutyric
acid, respectively, with concomitant production of ammonia
and carbon dioxide.
Higher eukaryotic βUP belong to the nitrilase superfamily
of enzymes (Pace and Brenner 2001). The closest known
structural relative of human βUP is found in Drosophila
melanogaster (DmβUP) (Lundgren et al 2008), sharing
63 % amino acid sequence identity. In solution, DmβUP
exists as a mixture of oligomers but crystallizes as a
homooctamer. It has a helical-turn like structure that is con-
secutively built up from dimeric units. This is in contrast to
other members of the nitrilase superfamily that assemble their
homotetrameric or homohexameric native states in a markedly
different fashion, and is most likely because of an N-terminal
∼65 amino acid extension unique to βUPs.
βUP deficiency (MIM 606673) is an autosomal recessive
disease caused by mutations in the βUP gene, UPB1. The
UPB1 gene maps to chromosome 22q11.2, and consists of ten
exons spanning approximately 20 kb of genomic DNA
(Vreken et al 1999). To date, only 16 genetically confirmed
patients with βUP deficiency have been reported (van
Kuilenburg et al 2012). The clinical phenotype of these pa-
tients is highly variable, but tends to center around neurolog-
ical problems (van Kuilenburg et al 2012). However, in Japan,
four asymptomatic individuals have been detected through
newborn screening by gas chromatography-mass spectrome-
try (GC/MS), and the prevalence of βUP deficiency in Japan
has been estimated to be one in 6000 (Kuhara et al 2009).
Thus, the clinical presentation and biochemical and genetic
spectrum of patients with βUP deficiency are still largely
unknown.
In this study, we report genetic and biochemical anal-
ysis, and clinical follow-up findings, of 13 Japanese
patients (including seven newly identified individuals)
with βUP deficiency. Functional and structural conse-
quences of the mutations at the protein level were
analysed using a eukaryotic expression system and a homol-




Patients 1, 2 and 3, who presented with neurological abnor-
malities during early childhood were detected through a high-
risk urine screening for general metabolic disorders performed
at KanazawaMedical University (Ohse et al 2002). In general
patients are tested for metabolic disorders if patients presented
with developmental delay, hyperammonemia, metabolic aci-
dosis and neurological manifestations such as convulsions,
autism and related disorders. Patients 4–7 and 8–13
were from two different areas in Japan, detected in a
pilot study screening for inborn errors of metabolism by
GC/MS in newborn urine samples, and conducted at
Kanazawa Medical University (Kuhara et al 2009) (pa-
tients 4–7) and Kurume University (patients 8–13). After
informed consent was obtained from their parents, urine and
blood samples from all patients were sent to the Laboratory for
Genetic Metabolic Diseases in Amsterdam, the Netherlands
for further analysis.
Quantitative pyrimidine analysis
On the basis of a gross elevation of N-carbamyl-ß-alanine and
N-carbamyl-ß-aminoisobutyric acid in urine screening for
inborn errors of metabolism by GCMS (Ohse et al 2002), ß-
ureidopropionase deficiency was suspected. Subsequently,
quantitation of relevant pyrimidines and its metabolites was
performed by HPLC tandem mass spectrometry.
Concentrations of uracil, thymine, dihydrouracil,
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dihydrothymine, N-carbamyl-β-alanine and N-carbamyl-β-
aminoisobutyric acid, in urine-soaked filter paper strips, were
determined using reversed-phase HPLC-tandem mass spec-
trometry (HPLC-MS/MS) (van Kuilenburg et al 2004c; van
Lenthe et al 2000).
PCR amplification of UPB1 coding exons
DNAwas isolated from whole blood or blood spots using the
QIAamp DNA Micro kit (QIAGEN). Exons 1-10 and
flanking intronic regions of UPB1, were amplified using
previously described primer sets (van Kuilenburg et al
2004a). UPB1 sequence from patients was compared to con-
trols and the reference UPB1 sequence (Ref Seq
NM_016327.2).
Cloning and site-directed mutagenesis
An expression plasmid containing wild-type human βUP
cDNA (pSE420-βUP) was constructed by subcloning the
complete coding region of human UPB1 into the NcoI-NaeI
site of the pSE420 vector (Vreken et al 1999). The UPB1
coding sequence was then re-cloned into the BamHI-KpnI site
of the pcDNA3.1Zeo vector, which includes coding sequence
for a cleavable C-terminal 6-His-fusion tag. To intro-
duce mutations, the pcDNA3.1Zeo plasmid containing
wild-type UPB1 was subjected to site-directed mutagen-
esis. Compatible primers (Table 1S, Supplementary data)
were designed for use with the QuikChange™ Site-
Directed Mutagenesis Kit (Life technologies). PCR-
mediated site-directed mutagenesis was performed according
to the manufacturer’s recommended protocol. All resulting
plasmids were sequenced to confirm introduction of single
nucleotide changes.
Cell culture and transient transfection
HEK293 cells were cultured in Dulbecco’s modified eagle’s
mediumwith 4.5 g/L glucose, 25 mMHepes and 584 mg/L L-
glutamine (Lonza), supplemented with 10 % fetal bovine
serum, 100 U/ml penicillin, 100 mg/ml streptomycin and
250 μg/ml fungizone at 37 °C in a humidified 5 % CO2
incubator. For transient transfections, cell cultures were set
up in six-well plates 24 h prior to transfection. HEK293 cells
were transfected with pcDNA3.1Zeo-βUP (wild-type or
variants) using X-treme GENE HP DNA Transfection
reagent (Roche). Two days after transfection, cells were
harvested and washed with PBS. After centrifugation at
1000×g for 5 min at 4 °C, cell pellets were immediately
frozen in liquid nitrogen and stored at−80 °C until use. All
transfections were performed in at least triplicate. Parental
vector (pcDNA3.1Zeo) without insert was transfected as neg-
ative control.
βUP enzyme activity assay
Cell pellets were resuspended in 300 μl isolation buffer
(35 mM potassium phosphate, pH 7.4 and 2.5 mM
MgCl2) and lysed by sonication on ice. Crude lysates
were centrifuged at ≥ 11,000 rpm for 20 min at 4 °C,
and then supernatant protein concentrations and βUP
enzyme activity of the expressed protein directly quan-
tified. βUP activity was determined at 37 °C in a
standard assay mixture containing cell supernatant, 200 mM
Mops (pH 7.4), 1 mM dithiothreitol and 500 μM [14C]-N-
carbamyl-β-alanine, as described previously (Van Kuilenburg
et al 1999).
Western blot analysis
Cell supernatants containing 5μg protein were fractionated on
NuPAGE® 4–12 % Bis-Tris Mini Gels (Life technologies)
and transferred to nitrocellulose membranes. Membranes
were blocked using Odyssey blocking buffer (LI-COR).
Subsequently, blots were incubated for one hour with a
1:1000 dilution of rabbit anti-UPB1 (Anti-UPB1 AV42467-
100UG, Sigma-Aldrich) and 1:5000 dilution of mouse anti-
alpha-tubulin antibodies in blocking buffer (50 % Odyssey
blocking buffer, 50 % PBS and 0.1 % Tween). Membranes
were washed three times and then incubated for one hour with
a 1:10,000 dilution of IRDye800 conjugated goat anti-rabbit
and IRDye680 conjugated donkey anti-mouse (both LI-COR)
secondary antibodies, in the same blocking buffer as used for
primary antibodies, with 0.01% SDS. Blots were scanned and
band intensities analysed using the LI-COR Odyssey infrared
imaging system.
Native gel electrophoresis
Blue native polyacrylamide gel electrophoresis was per-
formed using 4–16 % NativePAGE™ Novex® Bis-Tris Gels
(Life technologies). Supernatant samples were prepared in
sample buffer (50 mM Bis Tris, 6 N HCL, 50 mM NaCl,
10 % glycerol and 0.001 % Ponceau S, pH 7.2), and 5 μg
protein loaded. Electrophoresis was performed at 100 V
for 2 h at room temperature. Gels were transferred onto
PVDF membranes and immunoblotting performed, as
described above. NativeMark™ Unstained Protein
Standard (Life technologies) was used as a molecular
weight marker, and visualized with Ponceau S staining after
western transfer.
Crystal structure analysis
A homology model of human βUP was generated using the
SWISSMODEL server, based on the crystal structure of
Drosophila melanogaster βUP (DmβUP) (PDB-ID:2vhi
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and 2vhh) (Lundgren et al 2008). WinCoot (Emsley et al
2010) was used for structural analysis and manual introduc-
tion of amino acid exchanges resulting fromUPB1mutations.
Energetically preferred side chain conformations causing the
least steric clashes and optimal interactions with surrounding
residues were chosen. Figure 1 was generated using PyMol
(DeLano 2002).
Genotyping of c.977G > A by PCR-based restriction fragment
length polymorphism (PCR-RFLP) analysis
A 333 bp fragment of genomic DNA was amplified using a
primer set used for mutation analysis of exon 9 of the UPB1
gene. The amplified product was digested using the restriction
enzyme MspI, for 2 h at 37 °C. Transition of G to A at c.977
Fig. 1 DmβUP crystal structure and mutation site environment in the
homology model of human βUP. (a) Schematic view of homooctameric
DmβUP with each subunit coloured differently. (b) Schematic view of a
dimeric unit of DmβUP. For one of the subunits,β-strands are depicted in
green, helices in yellow-green and loops in white, with the other subunit
coloured salmon. Mutation sites are highlighted by space-filling models
of the respective amino acid side chains in magenta. Labels first list the
corresponding site in DmβUP. Location of the active site is indicated by
space-filling models of the active site cysteine (C233 in human βUP,
C234 in DmβUP) in yellow. (c-e) Enlarged views of I286T, G31S and
E271K mutation sites. The homology model of human βUP is shown
with different colours (salmon and green) for two separate subunits.
Additional subunits were omitted as none of the mutations occur near
putative interfaces. Stick models of side chains introduced by the muta-
tions are shown in magenta, in preferred conformations causing the least
clashes. Native side chains and residues surrounding the site are depicted
with carbon atoms in the same colour as the subunit to which they belong.
DmβUP side chains are shown with yellow carbon atoms when not
conserved in human βUP. Labels indicate human βUP residues followed
by corresponding DmβUP residues (if shown), with numbering for the
latter only when it differs. Hydrogen bonds are indicated by dotted black
lines. In (d), the loop directly following the G31S site is extended by one
amino acid in DmβUP (shown in yellow). In (d) and (e), corresponding
mutation sites in the second subunit of the dimer are marked by a magenta
sphere in the background
804 J Inherit Metab Dis (2014) 37:801–812
abolishes a restriction site in the mutant allele. Digested prod-
ucts were separated on 2.8 % agarose gels stained with
ethidium bromide. Genotypes were identified as wild-type
(GG) (three bands of 192, 153 and 24 bp), heterozygous
mutant (GA) (bands of 216, 192, 153 and 24 bp), or homo-
zygous mutant (AA) (bands of 216 and 153 bp).
In addition, the frequency of the c.977G > A mutation was
assessed in the exome variant server (EVS) of the National
Heart, Lung, and Blood Institute GO Exome Sequencing
Project (Seattle, WA, USA; URL: evs.gs.washington.edu/
EVS/) with the corresponding nucleotide positions being
analysed in >8.000 European and >4.000 African American
alleles, and in the Database of Single Nucleotide
Polymorphisms (dbSNP; Bethesda: National Center for
Biotechnology Information, National Library of Medicine




All patients were born to healthy non-consanguineous
Japanese parents. Patient 1 was a girl born at full term follow-
ing an uneventful delivery. At the age of two months, she was
irritable and had occasional jerky eye movements, with im-
pairment of visual contact noticed. Aweek later she presented
with infantile spasms, and head-nodding three to four times a
day. Cortical dysplasia was suspected from head MRI, and
EEGs showed hypsarrhythmia. She was diagnosed with West
syndrome. Biochemical investigation of urine obtained during
her first admission revealed significantly increased levels of
N-carbamyl-β-alanine and N-carbamyl-β-aminoisobutyric
acid (Kuhara et al 2009). The infantile spasms and abnormal
EEGs did not respond to zonisamide, therefore adrenocorti-
cotropic hormone (ACTH) therapy was started at three
months of age, and subsequently, the seizures disappeared
and EEG abnormalities subsided. At the age of 5 years, she
had partial seizures occasionally but her development was
within the normal range.
Patient 2 was a 3-year old boy who presented with autism
and mild mental retardation. At the age of 18 months, his
parents noticed social communication impairments, including
eye-to-eye gazing, facial expression, and language under-
standing. At the age of 3.5 years, he was diagnosed with
autism. When he was 8 years old, he developed a sleep
disorder and melatonin treatment was started. The Wechsler
Intelligence Score for Children test, performed at 11 years of
age, revealed a full scale IQ of 71, verbal IQ of 66, and
performance IQ of 83. He now attends a special-needs school.
Patient 3 was a 12-month old boy who presented with mild
hypotonia and motor developmental delay. The family history
found a 15-year old male cousin from the paternal side suffers
from epilepsy and autism related disorder. At the follow-up
age of 2.8 years, his motor development caught up to the
normal range but he has developed mild mental retardation,
particularly in speech development.
Patients 4–7 were detected through neonatal screening
performed from 1996 to 2009 in Kanazawa (Kuhara et al
2009). Since screening, they have been followed regularly
by an attending paediatrician. Patient 4 is a boy who devel-
oped neurological symptoms during the follow-up period. At
the age of 12 months, he had an attack of sudden-onset
consciousness impairment, a blank stare, and unresponsive-
ness which lasted for 2–3 min. A year after this epi-
sode, he developed febrile seizures that occurred four
times. One of the attacks lasted over 30 min and was
not easily controlled. The laboratory investigation at
admission showed no abnormalities. His fever abated the
following day and he regained consciousness. Further inves-
tigations by head MRI and EEG were normal. He has had no
seizures since 3 years of age, owing to the use of diazepam
suppositories during fevers. At 5 years of age, he has normal
growth and development.
Patients 5 and 6 are twin sisters, born at 36 weeks gestation
with birth weights of 2042 g and 2378 g, respectively. During
a follow-up period of 5 years, patient 6 showed no physical
examination abnormalities. Patient 5 has a height within the
3–10 percentile range and has developed hypermetropia.
Patient 7 is a 10-year-old boy with an unremarkable history
and no clinical manifestations during follow-up. Patients 8–13
were detected from newborn screening performed in Kurume
during a period from February 2010 to January 2012. None of
them showed abnormal developmental milestones at follow-
up evaluation.
Pyrimidine bases and degradation metabolites in urine
Urinary quantitative analysis of relevant pyrimidines and me-
tabolites was performed by HPLC-MS/MS. Urinary concen-
trations of the 13 patients are shown as subdivided genotype
groups (Fig. 2). All urine samples from the patients showed
strongly elevated levels of N-carbamyl-β-alanine and N-
carbamyl-β-aminoisobutyric acid, and moderately elevated
levels of dihydrouracil and dihydrothymine. Mean concentra-
tions of uracil (25.5±11.4 μmol/mmol creatinine), thymine
(3.6±1.9 μmol/mmol creatinine), dihydrouracil (57±
27 μmol/mmol creatinine), and dihydrothymine (127±
65 μmol/mmol creatinine), were 2-, 7-, 9-, and 41–fold,
respectively, higher compared with mean concentrations ob-
served in controls. Additionally, mean concentrations of N-
carbamyl-β-alanine (648±208 μmol/mmol creatinine) and N-
carbamyl-β-aminoisobutyric acid (504±297 μmol/mmol cre-
atinine) were 59-and 276-fold, respectively, higher compared
to mean concentrations observed in controls. The observed N-
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carbamyl-β-amino aciduria in these patients strongly suggests
βUP deficiency.
Mutation analysis of UPB1
Sequencing exons 1–10 (including flanking intronic regions)
of UPB1 in the 13 patients, identified one previously de-
scribed missense (c.977G>A) and three novel missense
(c.91G>A, c.811G>A, and c.857 T>C) mutations
(Table 1). This table also includes 15 patients (from 12 fam-
ilies) with βUP deficiency, and previously published muta-
tions (Assmann et al 1998; Assmann et al 2006; van
Kuilenburg et al 2012; Yaplito-Lee et al 2008). All 13
Japanese patients were carriers of the c.977G>A (p.R326Q)
mutation,with eight patients being homozygous for thismutation
(Table 1). Distribution of the UPB1 mutations within the
exons is shown (Fig. 3a). All previously identified mutations
and the three novel missense mutations were located in exons
1, 2, and 6–10.
Functional analysis and expression of mutant βUP protein
Recombinant wild-type and four βUP proteins contain-
ing the mutations, p.G31S, p.E271K, p.I286T, and
p.R326Q, were expressed in HEK293 cells. No endog-
enous βUP activity (< 0.7 nmol/mg/h) was detected in
HEK293 cells. Activity of wild-type βUP protein was
1976±416 nmol/mg/h (n=9). Recombinant βUP en-
zymes carrying mutations p.E271K and p.R326Q, exhib-
ited 0.7 and 1.3 %, respectively, of wild-type activity, whereas
βUP enzymes containing mutations p.G31S and p.I286T,
possessed residual activities of 51.6 and 69.8 %, respectively
(Fig. 3b).
Immunoblot analysis of expression levels of βUP mutant
proteins in soluble extracts from transfected HEK293 cells,
showed mutant proteins were expressed in comparable
amounts as wild-type protein (Fig. 3c).
Western blotting of blue native gels detected various high
molecular weight oligomeric forms of wild-type βUP, com-
parable or identical to that observed for βUP enzymes con-
taining p.G31S and p.I286T mutations. In contrast, no distinct
sharp bands of high molecular weight were observed for βUP
enzymes containing p.E271K and p.R326Q mutations, al-
though bands of lower molecular weights were present,
corresponding to lower oligomeric states (from mono-
mers to octamers) of βUP (Fig. 3d). These lower molecular
weight species were also observed in extracts from wild-type,
p.G31S and p.I286T expressing cells, albeit with evidently
lower intensity. This indicates that p.E271K and p.R326Q
proteins have a dramatically reduced ability to form larger
oligomers, and thus, their potential equilibrium of oligomeri-
zation status was shifted towards lower molecular weight
species.
Population study of βUP deficiency and the p.R326Q
mutation
Three patients with βUP deficiency were identified out of
4500 patients of a high-risk screening group demonstrating
that the prevalence ofβUP deficiency in a high-risk screening
group is one in 1500. PCR-RFLP analysis of the c.977G>A
(p.R326Q) mutation was performed in 110 Japanese healthy
controls. We identified two individuals heterozygous for the
p.R326Qmutation, and no homozygous individuals, resulting
in a frequency of heterozygotes in the Japanese population of
1.8 % (an allele frequency of 0.91 %). Analysis of publically
available databases showed that the c.977G>A mutation was
not detected in >8.000 European and >4.000 African
American alleles whereas the mutation was detected with an
allele frequency of 2.6 % in 286 individuals of East Asian
ancestry.
Analysis of the structural effects of UPB1 mutations
by homology modelling
A homology model of human βUP was generated to
predict the effect of the UPB1 mutations on enzyme
structure. High sequence similarity between homologous
enzymes at mutation sites (with G31 and E271 being
strictly conserved in deposited βUP sequences, and I286
replaced by leucine in rodent enzymes only) suggests
the mutations occur within structurally conserved
regions.
I286 is located in the subunit core, approximately at
10 Å distance from the active site (Fig. 1b). It is
surrounded by hydrophobic and polar residues (Fig. 1c).
The increase in side chain polarity upon mutation to thre-
onine may therefore be tolerated, and structural adjustments
limited to orientation of the hydroxyl group towards polar
neighbours and re-optimization of side chain packing, with
minor effects on active site geometry and enzymatic activ-
ity. This correlates well with the measured residual activity,
and unaltered behaviour of the mutant protein in native gel
analysis.
G31 is located directly downstream of a helix involved in
dimer interface formation in DmβUP (Fig. 1d) (Lundgren et al
2008). Mutation to serine requires structural rearrangement as
the close proximity of S325 leaves little space for a side chain.
Fig. 2 Pyrimidine and metabolite concentrations in urine of βUP
deficient patients and controls. Patients are classified in terms of their
genotype. (a) N-carbamyl-β-alanine, (b) N-carbamyl-β-aminoisobutyric
acid, (c) dihydrouracil, (d) dihydrothymine, (e) uracil, and (f) thymine. In
controls, the top, bottom and line through the middle of a box, correspond
to the 75th, 25th and 50th percentiles, respectively. Whiskers on the
bottom extend from the 2.5th percentile, and on the top, the 97.5th
percentile
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Taking into account that several previously identified delete-
rious mutations also cluster at oligomerization surfaces (van
Kuilenburg et al 2012), the significant loss in enzyme activity
is most likely linked to disturbance of subunit interactions.
Interestingly, native gel electrophoresis showed that only for-
mation of larger assemblies (those exceeding the size of
octamers) is hampered.
In DmβUP, the glutamate corresponding to E271 interacts
with two basic residues that are both conserved in the human
enzyme (H237, R236) (Fig. 1e). For the E271K mutant,
clashes of lysine 271 with nearby residues, and placement of
its positively charged head group in a hydrophobic (L267,
I277 and F356) or similarly charged environment (H237
and R236), will have severely destabilizing effects, fur-
ther amplified by the proximity of corresponding muta-
tion sites of two subunits at the dimer interface (Fig. 1e).
Structural changes to accommodate the altered side chain
are likely to affect oligomerization, as confirmed by native gel
electrophoresis (Fig. 3d). As the helix carrying E271 is
placed beside the one harbouring C233, any shifts in its
position may also directly influence active site geometry
and cause the observed dramatic loss of enzymatic
activity.
Discussion
βUP deficiency is described as exhibiting variable phenotypic
presentation, ranging from early infantile onset with severe
neurological involvement, to mild developmental delay and
learning disabilities, to asymptomatic individuals (van
Kuilenburg et al 2012). Despite large variation in clinical
presentation, the majority of previously identified patients
(85 %) present with MRI abnormalities (van Kuilenburg
et al 2012). In the present study, only three of the 13 patients
had neurological problems during infancy, and underwent
biochemical urine analysis as part of diagnostic examinations.
Ten of the patients were identified through newborn screening
programs. Follow-up clinical investigation revealed that one
of these patients had suffered from an episode of unconscious-
ness, and later developed febrile seizures. To date, the nine
other individuals have remained asymptomatic. As the follow-
up period of some patients (specifically, patients 8–13) is
relatively short, being only one to two years, it is conceivable
that more patients may present with a clinical phenotype in
due course.
The clinical phenotype of patients with DHP and DPD
deficiencies, the other two biochemical defects occurring
Fig. 3 (a) Schematic
representation of genomic
organization of the UPB1 gene.
UPB1 consists of ten exons
encoding an open reading frame of
1152 bp (depicted in grey). The
mutations identified to date in
βUP deficient patients are
indicated, with numbers
corresponding to cDNA positions.
(b) Expression of βUP mutants in
HEK293 cells. Residual
enzymatic activity ofβUPmutants
are expressed as percentages of
wild-type βUP activity. For each
construct, columns show mean
values and standard deviations
derived from at least three
transfections. (c) Western blot
analysis of HEK293 cells
expressing wild-type and mutant
βUP. Total cell protein (5 μg) was
resolved by SDS-PAGE followed
by immunoblotting against βUP
and alpha-tubulin. (d) Native
polyacrylamide gel electrophoresis
of HEK293 cells expressing βUP
protein (wild-type and mutants).
Cell supernatants (5 μg) were
subjected to 4–16 % blue native
page, followed by western blot
analysis using polyclonal
anti-βUP antibody
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within the pyrimidine degradation pathway, is highly variable,
ranging from severely (neurologically) affected to symptom-
less. The underlying pathogenesis of these variable clinical
manifestations of pyrimidine degradation disorders remains,
as yet, unknown. However, similarities between clinical phe-
notypes of patients with βUP deficiency, and DHP and DPD
deficiencies, suggests loss of physiological function of the
absent pathway metabolites, rather than toxicity of the accu-
mulated metabolite, is the underlying cause. In this respect,
patients with pyrimidine degradation defects show normal to
slightly decreased β-alanine levels in plasma and normal
levels in CSF, whereas β-aminoisobutyric acid concentrations
are strongly reduced in plasma and CSF (van Kuilenburg et al
2004a, b, 2008). β-Aminoisobutyric acid is not only a partial
agonist of the glycine receptor (Schmieden and Betz 1995),
but has also been demonstrated to enhance leptin secretion in
adipose cells (Begriche et al 2010). Leptin and its receptors are
widespread within the central nervous system, and leptin has
been shown to exert a neuroprotective effect in damaged brain
regions (Signore et al 2008). Therefore, altered β-
aminoisobutyric acid homeostasis in patients with pyrimidine
degradation defects may contribute to neurological abnormal-
ities. Treatment of a ßUP-deficient patient with ß-alanine for
over 1.5 years did not result in a clinical improvement
(Assmann et al 2006). So far, the clinical effect of ß-
aminoisobutyric acid supplementation has not been investi-
gated in ßUP-deficient patients. Considering the pivotal role
of βUP in β-alanine and β-aminoisobutyric acid synthesis,
we suspect it is unlikely that βUP deficiency is not related at
all to the neurological presentation observed in some of our
patients. However, our observation that patients with βUP
deficiency can present without any clinical abnormalities sug-
gests additional factors are involved in the clinical outcome.
These additional factors likely include alterations in other
genes and/or environmental factors.
Until now, eight missense and three splice site mutations in
UPB1 have been identified in patients with βUP deficiency
(van Kuilenburg et al 2012). In this study, we identified three
novel missense mutations and one recently reported mutation,
p.R326Q, in 13 patients from 12 unrelated Japanese families.
It is noteworthy that homozygosity of the p.R326Q mutation
is observed in 62 % (8/13) of Japanese patients, and all 13
patients carried this mutation on one or both alleles, resulting
in an allele frequency of 81 % (21/26) in Japanese patients
with βUP deficiency. Based on the fact that 1.8 % of the
Japanese population is heterozygous for the p.R326Q muta-
tion, we estimate that one individual per 12,500 will be
homozygous for the p.R326Q mutation. Thus, compared with
other frequently occurring inborn errors of metabolism, such
as phenylketonuria (1:70,000 in Japan), the expected preva-
lence ofβUP deficiency is not as rare as generally considered.
The fact that none of the patients identified through newborn
screening had lasting neurological problems, in combination
with the high estimated prevalence in Japan and variable fea-
tures in diagnosed patients, may indicate that the disease has
low penetrance and is a risk factor. However, it may be too early
to conclude that penetrance is low as we cannot exclude the
possibility that these patients will develop symptoms later on in
life. In addition, the prevalence of ß-ureidopropionase deficien-
cy in a high-risk group is four-times higher (1:1500) than that
observed in a control population (1:6000) (Kuhara et al 2009).
This observation suggests that ß-ureidopropionase deficiency
might be involved in the onset of a clinical phenotype.
Expression of mutant βUPs showed that p.E271K and
p.R326Q mutants exhibit significantly decreased residual ac-
tivity, whereas p.G31S and p.I286T mutants have more than
50% residual activity of wild type. This result is to some extent
in agreement with the finding that the two patients heterozy-
gous for p.G31S present with relatively low urinary N-
carbamyl-β-aminoisobutyric acid concentrations, although this
was not apparent in two siblings heterozygous for p.I286T
(Fig. 2). In combination with the blue native gel analysis, there
is no convincing evidence that the p.G31S or p.I286T muta-
tions are pathogenic. Since no DNA of the parents was avail-
able, carriership analysis of the mutations could not be per-
formed. Therefore, it is conceivable that c.91G > A (p.G31S)
and c.857 T > C (p.I286T) are in cis with c.977G > A
(p.R326Q). Thus, we cannot exclude the possibility that addi-
tional mutations may be present within non-coding regions of
UPB1 in patients carrying p.G31S or p.I286T mutations.
Recently, heterologous expression of p.R326Q mutant βUP
in E.coliwas shown to result in mutant enzyme with no residual
activity (van Kuilenburg et al 2012). Similarly, in the present
study, expression of p.R326Q mutant enzyme in HEK293 cells
caused a dramatic decrease in residual activity. The wide-
ranging urinary levels of N-carbamyl-β-alanine and N-
carbamyl-β-aminoisobutyric acid observed in patients homozy-
gous for the p.R326Qmutation (Fig. 2), suggest there is no clear
correlation between urinary biochemical phenotype and geno-
type in this group of patients. In addition, identification of the
p.R326Q mutation in both neurologically affected patients and
unaffected individuals indicates the severity of βUP deficiency
is not determined exclusively by UPB1 mutant alleles alone,
and other (epi)genetic factors modulate the effect of the final
functional enzyme (Dipple and McCabe 2000; Sriram et al
2005).
Analysis of the homology model of human βUP, revealed
that none of the mutation sites are found in or very near the
active site. Instead, the two exchanges most deleterious to
enzymatic activity occur at subunit surfaces that are buried
upon dimerization. As a similar observation was made for
previously reported point mutations of the humanUPB1 gene,
it appears that proper subunit association of dimers or larger
oligomers is required for full functionality of the encoded
enzyme. This can most simply be explained in terms of
enzyme stability. Alternatively, human βUP activity may be
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affected by ligand-induced changes in the oligomerization
state, as described for the rat liver enzyme and bacterial
homologues (Matthews et al 1992; Thuku et al 2007;
Stevenson et al 1992; Nagasawa et al 2000). However, such
potential regulatory properties of human βUP remain to be
further investigated.
The pyrimidine degradation pathway is also responsible for
degradation of the chemotherapeutic drug, 5-fluorouracil (5-
FU). It is well known that patients with either complete or
partial DPD deficiency can show severe toxicity after 5-FU
administration (van Kuilenburg 2004; van Kuilenburg et al
2000). Furthermore, it has been demonstrated that patients
with partial DHP deficiency are prone to develop severe 5-
FU toxicity (van Kuilenburg et al 2003), and heterozygous
mutations in the UPB1 gene may impair uracil catabolism
(Fidlerova et al 2012; Thomas et al 2008). Therefore, risk of
developing 5-FU toxicity is not limited to DPD deficiency,
and patients with βUP deficiency may also be at risk of
developing severe 5-FU toxicity.
Our study shows that even though the clinical manifesta-
tion of βUP deficient patients varies considerably from symp-
tomless to severely neurologically affected, high frequency of
the p.R326Q mutation in Japanese patients, and relatively
high prevalence of the p.R326Q mutation in the Japanese
population, suggests there may be additional undiagnosed
patients with βUP deficiency. Thus, pyrimidine degradation
defects should be included in differential diagnosis of unex-
plained neurological abnormalities, such as convulsions, de-
velopmental delay, autism and related disorders.
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